Biomarin Pharmaceutical Inc. (BMRN): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Biomarin Pharmaceutical ( BMRN) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.3%. By the end of trading, Biomarin Pharmaceutical rose $0.75 (1.3%) to $58.79 on average volume. Throughout the day, 1,196,674 shares of Biomarin Pharmaceutical exchanged hands as compared to its average daily volume of 1,474,600 shares. The stock ranged in a price between $57.06-$58.98 after having opened the day at $57.88 as compared to the previous trading day's close of $58.04. Other companies within the Health Care sector that increased today were: CardioNet ( BEAT), up 55.5%, Progenics Pharmaceuticals ( PGNX), up 31.0%, Vanda Pharmaceuticals ( VNDA), up 25.0% and Rexahn Pharmaceuticals ( RNN), up 19.1%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Biomarin Pharmaceutical has a market cap of $8.2 billion and is part of the drugs industry. Shares are up 19.8% year to date as of the close of trading on Monday. Currently there are 14 analysts that rate Biomarin Pharmaceutical a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Biomarin Pharmaceutical as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity.

On the negative front, Biota Pharmaceuticals ( BOTA), down 67.6%, Symmetry Medical ( SMA), down 14.9%, GenMark Diagnostics ( GNMK), down 12.9% and Cardium Therapeutics ( CXM), down 12.2% , were all laggards within the health care sector with Covidien ( COV) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Trump's FDA: A Friendlier Biotech Sheriff

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Why I Hate the FAANGs (but Like Banks and Biotech) for 2017's Second Half

3 Fearless Predictions for the Second Half